Company News

Launched last July, starting with Africa and Middle East, the E-Resale platform allows to purchase and sell second-hand bioMérieux instruments for clinical applications. This is an innovative offer in the field of circular economy and a first on the in vitro diagnostics market.

On November 14th, 2024, bioMérieux officially launched its first Data & IT Centre of Reference partnership with St James's Hospital in Dublin, Ireland. This landmark collaboration has been celebrated with an event held at the Davis Coakley Lecture Theatre, St James's Hospital.

Globally, it was estimated that approximately 4.95 million people died from Antimicrobial Resistance-related causes in 2019. And yet, one in three adults doesn’t understand what this term means. Faced with this alarming situation, an awareness-raising campaign encourages the general public to change their behaviour with regard to the use of antibiotics. Indeed, each person, at their own level, has a role to play to preserve their effectiveness.

On November 11, 2024, the Université de Sherbrooke (UdeS), the Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS) and bioMérieux, a world leader in the field of in vitro diagnostics, announce a three-year agreement to create a Canadian center of excellence dedicated to the fight against antimicrobial resistance and antibiotic stewardship.

bioMérieux, a world leader in the field of in vitro diagnostics, signed in November 2024 a Sale and Purchase Agreement (SPA) to acquire Neoprospecta. This company, based in Florianopolis, Brazil, develops and markets innovative user-friendly data and genomics solutions for augmenting quality assurance programs and improve microbiological risk prevention in food and pharma industries.